Related Experiment Video

Updated: May 23, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Target points in trastuzumab resistance

Sahar Shojaei1, Mossa Gardaneh, Abbas Rahimi Shamabadi

  • 1National Institute of Genetic Engineering and Biotechnology (NIGEB), Pajoohesh Boulevard, Tehran-Karaj HWY, Km 15, Tehran 1497716316, Iran.

International Journal of Breast Cancer
|April 7, 2012
PubMed

Insights

Targeted therapy for HER2-positive breast cancer using trastuzumab faces resistance. Identifying a common signaling node could overcome resistance, improving treatment outcomes for breast and other cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Epidermal growth factor (EGF) receptors, including human EGF receptor 2 (HER2), regulate cell growth and differentiation.
  • HER2 overexpression correlates with carcinogenesis, making it a target for breast cancer therapy.
  • Trastuzumab, a HER2-targeted antibody, is effective against HER2-positive breast tumors but resistance develops.

Purpose of the Study:

  • To investigate the mechanisms of trastuzumab resistance in HER2-positive breast cancer.
  • To identify a common central node in the interconnected intracellular signaling pathways driving resistance.
  • To explore potential therapeutic strategies to overcome trastuzumab resistance.

Main Methods:

  • Analysis of intracellular signaling pathways involved in trastuzumab resistance.
  • Identification of key effector molecules shared across different resistance mechanisms.
  • Exploration of potential common nodes central to these pathways.

Main Results:

  • Trastuzumab resistance involves complex, interconnected intracellular signaling pathways.
  • These pathways share common key effector molecules.
  • A central node coordinating these resistance mechanisms is hypothesized.

Conclusions:

  • Understanding the interconnected signaling pathways is crucial for overcoming trastuzumab resistance.
  • Identifying a common node could lead to novel therapeutic strategies for HER2-positive cancers.
  • Targeting this common node may offer a universal solution for trastuzumab resistance in breast and other cancers.

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...